TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches

Hematopoietic cell transplantation (HCT) in MDS patients of older age

Hematopoietic cell transplantation (HCT) has evolved to an essential treatment in younger and more recently in elderly patients with myelodysplastic syndrome (MDS), the age group with the highest incidence. Less intense conditioning regimens and improvements in supportive therapy have reduced considerably transplant related mortality and in the same time increased the access to this curative treatment. Timing of HCT in the course of the disease assumes a crucial role. Detection of disease progression, geriatric assessment, comorbidity evaluation, and identification of transplant-specific risks are becoming increasingly important in this context. Novel statistical methods, molecular biomarkers, and quantification of tumor burden pre- and post-HCT will play an essential role in years to come. More effective and less toxic treatments to reduce the tumor burden before and/or after HCT are expected to improve the outcome. In this review article we discuss the current views and what we can expect.

Targeted Combination Therapies: A New Frontier in the Treatment of TP53 and KRAS Mutation-Associated Cancers

This Patent Highlight discusses novel therapeutic strategies for treating cancers associated with TP53 or KRAS mutations, particularly colorectal, pancreatic, and non-small-cell lung cancers. It focuses on the use of combination therapies involving two distinct compounds and a KRAS inhibitor. Researchers are exploring the effectiveness of these combined therapies in patient treatment and investigating their potential applications in drug manufacturing. With cancer being a global health challenge, these innovative strategies could present a breakthrough in enhancing survival rates and improving the quality of life for patients.